Literature DB >> 8314353

Response of four human ovarian carcinoma cell lines to all-trans retinoic acid: relationship with induction of differentiation and retinoic acid receptor expression.

M J Caliaro1, C Marmouget, S Guichard, P Mazars, A Valette, A Moisand, R Bugat, S Jozan.   

Abstract

The response of 4 human ovarian carcinoma cell lines to retinoic acid was found to be related to the histological type and degree of differentiation of these tumor cells. The 2 serous cell lines NIHOVCAR3 and OVCCR1 were the most sensitive to the antiproliferative effect of RA. This inhibition was associated with morphological and biological changes that were indicative of differentiation. The undifferentiated IGROV1 cell line was not affected by RA. Since the effects of RA are thought to be mediated by nuclear retinoic acid receptors (RARs), the expression of RARs in human ovarian cancer cells was studied. RAR alpha was detected as mRNA species of 3.1 and 2.6 kb in all 4 cell lines. RAR beta was not detected in any of the cell lines, while RAR gamma (3 kb) was expressed in all of the ovarian cancer cells but at a very low level in the RA-resistant IGROV1 cells.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8314353     DOI： 10.1002/ijc.2910560522

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


  8 in total

1.  Synergistic effects of 8-Cl-cAMP and retinoic acids in the inhibition of growth and induction of apoptosis in ovarian cancer cells: induction of retinoic acid receptor beta.

Authors:  R K Srivastava; A R Srivastave; Y S Cho-Chung
Journal:  Mol Cell Biochem       Date:  2000-01       Impact factor: 3.396

2.  Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status.

Authors:  C D Katsetos; I Stadnicka; J C Boyd; H Ehya; S Zheng; C M Soprano; H S Cooper; A S Patchefsky; D R Soprano; K J Soprano
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

3.  Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer.

Authors:  Bulent Karabulut; Burcak Karaca; Umut Varol; Ugur Muslu; Burcu Cakar; Harika Atmaca; Asli Kisim; Selim Uzunoglu; Ruchan Uslu
Journal:  J Exp Clin Cancer Res       Date:  2010-07-30

4.  Differential expression of aldehyde dehydrogenase 1a1 (ALDH1) in normal ovary and serous ovarian tumors.

Authors:  Krishna Penumatsa; Seby L Edassery; Animesh Barua; Michael J Bradaric; Judith L Luborsky
Journal:  J Ovarian Res       Date:  2010-12-22       Impact factor: 4.234

5.  Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.

Authors:  M J Caliaro; P Vitaux; C Lafon; I Lochon; A Néhmé; A Valette; P Canal; R Bugat; S Jozan
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.

Authors:  G J Rustin; T G Quinnell; J Johnson; H Clarke; A E Nelstrop; W Bollag
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

7.  Methylation and silencing of the retinoic acid receptor-beta 2 gene in cervical cancer.

Authors:  Tatyana Ivanova; Anatolii Petrenko; Tatyana Gritsko; Svetlana Vinokourova; Ernest Eshilev; Vera Kobzeva; Fjodor Kisseljov; Natalia Kisseljova
Journal:  BMC Cancer       Date:  2002-03-21       Impact factor: 4.430

8.  Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.

Authors:  A Nehmé; P Varadarajan; G Sellakumar; M Gerhold; H Niedner; Q Zhang; X Lin; R D Christen
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.